ALG-094103 / Aligos Therap - LARVOL DELTA

Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer (SITC 2023) - "In the in vivo PD-L1 target occupancy model, oral dosing of ALG-094103 at 50 mg/kg demonstrated higher PD-L1 target occupancy than oral dosing of INCB086550 at 150 mg/kg and IV dosing of durvalumab at 5 mg/kg. Conclusions We have discovered a novel liver-targeted and orally bioavailable PD-L1 small molecule inhibitor, ALG-094103, with comparable in vitro potency to INCB086550. The properties of ALG-094103 will be further evaluated as a potential candidate for drug development."

Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor

DISCOVERY OF A LIVER TARGETED ORAL PD-L1 SMALL MOLECULE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B AND LIVER CANCER (AASLD 2023) - "In the in vivo PD-L1 target occupancy model, oral dosing of ALG-094103 at 50 mg/kg demonstrated higher PD-L1 target occupancy than oral dosing of INCB086550 at 150 mg/kg and IV dosing of durvalumab at 5 mg/kg. We have discovered a novel liver targeted oral PD-L1 small molecule inhibitor, ALG-094103, with similar in vitro potency to ALG-093702 and INCB08655, and with significantly improved oral bioavailability. ALG-094103 will be further evaluated as a potential candidate for drug development."

Gastrointestinal Cancer • Hepatitis B • Hepatology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor